Bioretec concludes change negotiations

Bioretec Ltd, Press Release, 17 June 2026 at 9:00 EEST

On 1 June 2026, Bioretec announced the initiation of change negotiations in accordance with the Finnish Act on Co-operation within Undertakings, focusing on the company’s production function in Finland. The aim of the negotiations was to streamline operations and consequently to improve the company’s competitiveness and profitability.

The negotiations began on 8 June 2026 and were concluded today.

At the start of the negotiations, the company estimated that the plans may impact the terms of employment of up to four individuals in Finland. As a result of the negotiations, the employment of three employees will be terminated.

A total of 12 employees from Bioretec’s staff in Finland were included in the scope of the negotiations.

Further enquiries

Tuukka Paavola, CFO, +358 50 386 0013

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.

Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com